Definium Therapeutics Inc (DFTX) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary

Conference overview

• The event featured over 20 companies with a focus on neurology, covering indications such as depression, epilepsy, Alzheimer's, ALS, and novel CNS drug delivery methods.

• The agenda included panels and fireside chats, emphasizing the latest advancements and differentiated approaches in brain health.

Company strategy and pipeline

• The organization restructured in 2021, growing to 60–65 employees and launching clinical programs, notably MM120 for generalized anxiety disorder (GAD).

• Focus is on developing scalable, accessible psychedelic-based drugs without assisted therapy, aiming for broad commercialization.

• MM120 is being advanced as a standalone treatment, with phase III trials planned for later this year.

• MM402, the R enantiomer of MDMA, is in development for autism spectrum disorder, targeting social communication deficits.

MM120 program and clinical data

• MM120 is a novel LSD formulation designed for stability, scalability, and intellectual property protection, using an orally dissolving tablet for improved pharmacokinetics.

• The phase II study was a 200-patient, 5-arm dose-response trial, showing rapid, durable, and statistically significant improvements in GAD symptoms.

• The 100 microgram dose group saw a 21-point improvement on the Hamilton Anxiety Scale, with effects emerging within 24 hours and lasting 12 weeks.

• The effect size was about double that of standard care, with robust blinding and minimal expectancy bias.

• Two phase III studies are planned to support NDA submission, with enrollment expected to begin by year-end.